Curculigoside

Research use only, not for human use.

Curculigoside can prevent bone loss , improve osteogenesis and inhibit osteoclastogenesis of hAFSCs, suggesting its potential use to regulate hAFSC osteogenic differentiation for treating bone disorders.

Curculigoside can prevent bone loss , improve osteogenesis and inhibit osteoclastogenesis of hAFSCs, suggesting its potential use to regulate hAFSC osteogenic differentiation for treating bone disorders. Curculigoside can promote calcium deposition and increase the levels of ALP and Runx2 in osteoblasts under oxidative stress via anti-oxidative character. Curculigoside possesses potent antioxidant properties against oxidative stress insults. can protect endothelial cells against oxidative injury induced by H2O2, suggesting that this compound may constitute a promising intervention against cardiovascular disorders.

Cell Viability Assay Cell Line:MH7A cells Concentration:1 μg/ml; 2 μg/ml; 4 μg/ml; 8 μg/ml; 16 μg/ml; 32 μg/ml; 64 μg/ml Incubation Time:72 hours Result:Had inhibitory effect on MH7A cells.Western Blot Analysis Cell Line:MH7A cells Concentration:4 μg/ml; 64 μg/ml Incubation Time:24 hours Result:Downregulated JAK1, JAK3 and STAT3 protein expression.

——

Curculigoside A | Curculigoside-A

Others

Other Targets

Antioxidant

Cardiovascular Disease

——

85643-19-2

466.43

C22H26O11

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (214.39 mM)

COC1=C(C(=CC=C1)OC)C(=O)OCC2=C(C=CC(=C2)O)OC3C(C(C(C(O3)CO)O)O)O

[5-Hydroxy-2-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]methyl 2,6-dimethoxybenzoate

(-20℃)

With Ice Pack

≥ 2 years